+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bronchodilators Market by Drug class, by Indication and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5019919
  • Report
  • February 2020
  • Region: Global
  • 207 pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Abbott Laboratories.
  • AstraZeneca
  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Hoffmann-La Roche
  • MORE
The global bronchodilators market was valued at $27,580.00 million in 2018 and is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Bronchodilators are drugs that relax muscles that tighten around the airways. These drugs open airways and allow more air to move in and out of lungs. They are also used to reduce mucus from lungs. Patients suffering from respiratory disorders consume these drugs through the help of nebulizers or inhalers. In addition, inhaler bronchodilators have effects on mucociliary clearance as well. Bronchodilators are used in the treatment of obstructive lung diseases by relaxing the lung muscles and widening the airways (bronchi). They are used in the treatment of asthma and chronic obstructive pulmonary diseases (COPD).



Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD) across the globe is the major factor driving the bronchodilators market growth. Other factors such as rise in incidence of respiratory diseases due to cigarette smoking also boost the market growth. In addition, rise in disposable income, geriatric population, and increase in awareness for healthcare among people are anticipated to boost the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of these drugs are anticipated to hamper the market growth. Furthermore, ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the market.

The market is segmented on the basis of indication, drug type, route of administration, and region. On the basis of indication, it is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. By drug type, it is classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitors, and combination drugs. On the basis of route of administration, it is categorized into oral, injection, and inhaler. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc., and Abbott Laboratories are provided in this report.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Indication
  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Others
By Drug Type
  • Sympathomimetics
  • Anticholinergics
  • Phosphodiesterase Inhibitor
  • Combination Drugs
By Route of Administration
  • Oral
  • Injection
  • Inhaler
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • F. Hoffmann-La Roche AG
  • AstraZeneca plc
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group plc.
  • Abbott Laboratories
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories.
  • AstraZeneca
  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Hoffmann-La Roche
  • MORE
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of asthma and COPD
3.5.1.2. Surge in government initiatives
3.5.2. Restraint
3.5.2.1. Side effects associated with bronchodilators
3.5.3. Opportunity
3.5.3.1. Various growth opportunities in emerging economies

CHAPTER 4: BRONCHODILATORS MARKET, BY INDICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Asthma
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Chronic obstructive pulmonary disease (COPD)
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
4.4. Others
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country

CHAPTER 5: BRONCHODILATORS MARKET, BY DRUG TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Sympathomimetics
5.2.1. Market size and forecast
5.2.2. Market share analysis, by country
5.3. Anticholinergics
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Phosphodiesterase Inhibitors
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. Combination Drugs
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country

CHAPTER 6: BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Injection
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.4. Inhalers
6.4.1. Market size and forecast
6.4.2. Market share analysis, by country

CHAPTER 7: BRONCHODILATORS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by drug type
7.2.5. Market size and forecast, by route of administration
7.2.5.1. U.S. market size and forecast, by indication
7.2.5.2. U.S. market size and forecast, by drug type
7.2.5.3. U.S. market size and forecast, by route of administration
7.2.5.4. Canada market size and forecast, by indication
7.2.5.5. Canada market size and forecast, by drug type
7.2.5.6. Canada market size and forecast, by route of administration
7.2.5.7. Mexico market size and forecast, by indication
7.2.5.8. Mexico market size and forecast, by drug type
7.2.5.9. Mexico market size and forecast, by route of administration
7.3. Europe
7.3.1. Key growth factors and opportunities
7.3.2. Europe Market size and forecast, by country
7.3.3. Europe Market size and forecast, by indication
7.3.4. Europe Market size and forecast, by drug type
7.3.5. Europe Market size and forecast, by route of administration
7.3.5.1. Germany market size and forecast, by indication
7.3.5.2. Germany market size and forecast, by drug type
7.3.5.3. Germany market size and forecast, by route of administration
7.3.5.4. France market size and forecast, by indication
7.3.5.5. France market size and forecast, by drug type
7.3.5.6. France market size and forecast, by route of administration
7.3.5.7. UK market size and forecast, by indication
7.3.5.8. UK market size and forecast, by drug type
7.3.5.9. UK market size and forecast, by route of administration
7.3.5.10. Rest of Europe market size and forecast, by indication
7.3.5.11. Rest of Europe market size and forecast, by drug type
7.3.5.12. Rest of Europe market size and forecast, by route of administration
7.4. Asia-Pacific
7.4.1. Key growth factors and opportunities.
7.4.2. Asia-Pacific market size and forecast, by country
7.4.3. Asia-Pacific market size and forecast, by indication
7.4.4. Asia-Pacific market size and forecast, by drug type
7.4.5. Asia-Pacific market size and forecast, by route of administration
7.4.6.1. Japan market size and forecast, by indication
7.4.6.2. Japan market size and forecast, by drug type
7.4.6.3. Japan market size and forecast, by route of administration
7.4.6.4. China market size and forecast, by indication
7.4.6.5. China market size and forecast, by drug type
7.4.6.6. China market size and forecast, by route of administration
7.4.6.7. India market size and forecast, by indication
7.4.6.8. India market size and forecast, by drug type
7.4.6.9. India market size and forecast, by route of administration
7.4.6.11. Rest of Asia-Pacific market size and forecast by indication
7.4.6.12. Rest of Asia-Pacific market size and forecast, by drug type
7.4.6.13. Rest of Asia-Pacific market size and forecast, by route of administration
7.5. LAMEA
7.5.1. Key growth factors and opportunities
7.5.2. Market size and forecast, by country
7.5.3. LAMEA market size and forecast, by indication
7.5.4. LAMEA market size and forecast, by drug type
7.5.5. LAMEA market size and forecast, by route of administration
7.5.5.1. Brazil market size and forecast, by indication
7.5.5.2. Brazil market size and forecast, by drug type
7.5.5.3. Brazil market size and forecast, by route of administration
7.5.5.4. Saudi Arabia market size and forecast, by indication
7.5.5.5. Saudi Arabia market size and forecast, by drug type
7.5.5.6. Saudi Arabia market size and forecast, by route of administration
7.5.5.7. South Africa market size and forecast, by indication
7.5.5.8. South Africa market size and forecast, by drug type
7.5.5.9. South Africa market size and forecast, by route of administration
7.5.5.10. Rest of LAMEA market size and forecast, by indication
7.5.5.11. Rest of LAMEA market size and forecast, by drug type
7.5.5.12. Rest of LAMEA market size and forecast, by route of administration

CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. AstraZeneca plc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline Plc.
8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. Novartis AG.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Pfizer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. SANOFI
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Vectura Group Plc.
8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
8.10.4. Business performance
Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • Abbott Laboratories.
  • AstraZeneca
  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Hoffmann-La Roche
  • MORE
According to the report titled 'Bronchodilatormarket by drug class, indication and route of administration: Global opportunity analysis and industry forecast, 2018-2026,' the global bronchodilatormarket size is expected to reach $41,487.53 million by 2026, registering a CAGR of 5.2% from 2019 to 2026, in terms of value. Bronchodilators are usually recommended as first‐line treatment for diseases in people with respiratory disorders. Albuterol (brand names Ventolin and Proventalin); Xopenex (levalbuterol); and Combivent, a combination of ipratropium bromide and albuterol, are bronchodilators used to treat bronchospasms caused due to cystic fibrosis. These are being widely used by patients as they suffer from difficulty in breathing due to mucus accumulation.

Significant increase in prevalence of cystic fibrosis, asthma, and other disorders across the globe is the major factor driving the bronchodilators market growth. Furthermore, other major factors driving the market growth are rise in concern regarding respiratory diseases, such as asthma and sympathomimetics and surge in incidences of respiratory diseases caused due to cigarette smoking. The market is anticipated to grow due to increase in healthcare expenditure, growth in use of homecare devices in the healthcare industry, and rapid adoption of advanced medical solutions. Presently, most healthcare practitioners and pulmonary diseases specialists prefer combination of a drug and a device, owing to its fast and effective outcome. However, the factors such as high cost associated with bronchodilators and side effects caused due to their excessive use hampers the market growth.

By indication, the asthma segment accounted for majority of the market share in 2018 and is expected to exhibit a prominent growth rate in the future. This is attributed to significant surge in the prevalence of asthma across the globe. For instance, according to the Asthma and Allergy Foundation of America, asthma accounts for 9.8 million hospital visits, 188,968 discharges from hospital inpatient care, and 1.8 million emergency department visits each year.

By drug type, the anticholinergics segment dominated the bronchodilators market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that anticholinergics are available in both long acting and short acting forms.

According to Onkar Sumant, Assistant Manager, Healthcare, “Significant surge in the prevalence of respiratory disorders across the globe is the major factor contributing to the market growth of bronchodilators market.

KEY FINDINGS OF THE STUDY
  • By indication, the asthma segment accounted for the highest market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
  • By region, North America was the major shareholder and accounted for the highest share of 45% in 2018.
  • By drug Type, the combination drugs segment is expected to grow at a CAGR of 5.4% during the forecast period.
  • By route of administration, the inhaler segment dominated the market in 2018, and is anticipated to maintain its dominance during the forecast period.
Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc and Abbott Laboratories. are provided in this report.
Note: Product cover images may vary from those shown
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Hoffmann-La Roche
  • AstraZeneca plc
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group plc
  • Abbott Laboratories.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll